The U.S. Food and Drug Administration has approved the first molecular-based laboratory test for detecting whether breast cancer has metastasized.
The GeneSearch BLN Assay test approved Monday detects molecules that are abundant in breast tissue but are scarce in a normal lymph node.
The FDA said the presence or absence of breast cancer cells in underarm lymph nodes is a strong predictor of whether the cancer has spread and is used to help decide appropriate therapy for women with metastatic breast cancer.
"The GeneSearch BLN Assay offers a new approach to sentinel node testing," said Dr. Daniel Schultz, director of the FDA's Center for Devices and Radiological Health. "Results of this rapid test are available while patients are on the operating table, providing a way for some women to avoid a second operation."
The GeneSearch BLN Assay is manufactured by Veridex, a Johnson & Johnson subsidiary located in Warren, N.J.
Copyright 2007 by United Press International
Related stories:
Test can reduce recurrence of breast cancer
A new test that examines large sections of the sentinel lymph node for genes expressed by breast cancer could reduce the risk of recurrence and multiple surgeries, doctors say.
New technique detects specific chromosomal damage, may indicate lung cancer risk
A new technique could pave the way toward screening people at risk for lung cancer for the genetic changes that may foreshadow malignancies, researchers from the University of Colorado say.
Nanoparticles can damage DNA, increase cancer risk
Tissue studies indicate that nanoparticles, engineered materials about a billionth of a meter in size, could damage DNA and lead to cancer, according to research presented at the 2007 Annual Meeting of the American Association for Cancer Research.
Tissue Geometry Plays Crucial Role in Breast Cell Invasion
Apropos of National Breast Cancer Awareness month, researchers with the U.S. Department of Energy’s Lawrence Berkeley National Laboratory have created a first-of-its-kind model for studying how breast tissue is shaped and structured during development. The model may shed new light on how the misbehavior of only a few cells can facilitate metastatic invasion because it shows that the development of breast tissue, normal or abnormal, is controlled not only by genetics but also by geometry.
Researchers combine nanotubes and antibodies to detect cancer
By coating the surfaces of tiny carbon nanotubes with monoclonal antibodies, biochemists and engineers at Jefferson Medical College and the University of Delaware have teamed up to detect cancer cells in a tiny drop of water. The work is aimed at developing nanotube-based biosensors that can spot cancer cells circulating in the blood from a treated tumor that has returned or from a new cancer.
Researchers unveil reliable new approach to cancer drug delivery
Prostate, breast and other cancer patients may be offered a new, stauncher targeted drug delivery system to treat their diseases in the next decade.
Using atomic force microscopy and computer simulations, researchers from Lawrence Livermore National Laboratory and the UC Davis Cancer Center have unveiled a new and reliable technique to characterize the binding interaction of multivalent molecules designed for targeted drug delivery in cancer treatment.
MetaChip provides quick, efficient toxicity screening of potential drugs
Researchers at the University of California, Berkeley, and Rensselaer Polytechnic Institute have created a biotech chip that mimics the metabolic reactions in the human liver, allowing rapid screening of potential drugs to identify those activated by the liver and to weed out those made toxic.
"The MetaChip would allow testing a backlog of compounds for toxicity earlier in the drug discovery process – faster and more efficiently – and help remove a current bottleneck in the drug discovery process," said Douglas S. Clark, professor of chemical engineering at UC Berkeley.
Parsing the genome of a deadly brain tumor
The most comprehensive to-date genomic analysis of a cancer – the deadly brain tumor glioblastoma multiforme – shows previously unrecognized changes in genes and provides an overall view of the missteps in the pathways that govern the growth and behavior of cells, said members of The Cancer Genome Atlas Research Network in a report that appears online today in the journal
Nature.